Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last621 to 640 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Asundexian vs Apixaban: Number of Participants With Composite of Disabling Stroke (mRS ≥ 3), Critical Bleeding, or All-cause Mortality | 51 of 7,373 56 of 7,364 | -0.1 points -0.3 to 0.2 | 14,737 | NCT05643573 A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke |
| Asundexian vs Apixaban: Number of Participants With Hemorrhagic Stroke | 1 of 7,373 6 of 7,364 | -0.1 points -0.2 to 0.0 | 14,737 | NCT05643573 A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke |
| Asundexian vs Apixaban: deaths from any cause | 73 of 7,373 85 of 7,364 | -0.2 points -0.5 to 0.2 | 14,737 | NCT05643573 A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke |
| Asundexian vs Apixaban: Number of Participants With Composite of ISTH Major or Clinically Relevant Non-major Bleeding | 83 of 7,373 188 of 7,364 | -1.4 points -1.9 to -1.0 | 14,737 | NCT05643573 A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke |
| Asundexian vs Apixaban: serious adverse events | 582 of 7,373 599 of 7,364 | -0.2 points -1.1 to 0.6 | 14,737 | NCT05643573 A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke |
| Exenatide Once Weekly vs Placebo: deaths from any cause | 507 of 7,344 584 of 7,372 | -1.0 points -1.9 to -0.2 | 14,716 | NCT01144338 Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus |
| Exenatide Once Weekly vs Placebo: serious adverse events | 1,234 of 7,344 1,222 of 7,372 | 0.2 points -1.0 to 1.4 | 14,716 | NCT01144338 Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus |
| EHR-based Referral to Quit Line vs Fax-based Referral to Quit Line: Number of Participants Self-reporting Smoking Abstinence | 34 of 7,481 14 of 7,155 | 0.3 points 0.1 to 0.5 | 14,636 | NCT02735382 EHR-Based and Fax-Based Referral to a Tobacco Quitline: A Comparative Study |
| EHR-based Referral to Quit Line vs Fax-based Referral to Quit Line: Number of Participants Referred | 1,380 of 7,481 331 of 7,155 | 13.8 points 12.8 to 14.8 | 14,636 | NCT02735382 EHR-Based and Fax-Based Referral to a Tobacco Quitline: A Comparative Study |
| EHR-based Referral to Quit Line vs Fax-based Referral to Quit Line: Number of Participants Meeting Criteria for Quality Referral | 400 of 7,481 121 of 7,155 | 3.7 points 3.1 to 4.3 | 14,636 | NCT02735382 EHR-Based and Fax-Based Referral to a Tobacco Quitline: A Comparative Study |
| Telmisartan vs Placebo: Number of Patients With New Onset of Diabetes (Telmisartan vs. Placebo Only) | 125 of 7,306 151 of 7,283 | -0.4 points -0.8 to 0.1 | 14,589 | NCT00153062 PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes |
| Intervention Arm vs Usual Care: deaths from any cause | 34 of 706 858 of 13,867 | -1.4 points -2.8 to 0.5 | 14,573 | NCT01609842 Hybrid Effectiveness-Implementation Study to Improve Clopidogrel Adherence |
| Intervention Arm vs Usual Care: serious adverse events | 99 of 706 1,782 of 13,867 | 1.2 points -1.3 to 4.0 | 14,573 | NCT01609842 Hybrid Effectiveness-Implementation Study to Improve Clopidogrel Adherence |
| Sitagliptin vs Placebo: serious adverse events | 928 of 7,266 909 of 7,274 | 0.3 points -0.8 to 1.4 | 14,540 | NCT00790205 Sitagliptin Cardiovascular Outcomes Study (MK-0431-082) |
| LTFU+Control >=50YOA Group vs Historical Control >=50 YOA Group: Number of Participants Having at Least One Confirmed Herpes Zoster (HZ) Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, Overall | 69 of 7,258 341 of 7,258 | -3.7 points -4.3 to -3.2 | 14,516 | NCT02723773 A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults |
| Phase I: Observational, Mother vs Phase I: Observational, Neonate: deaths from any cause | 3 of 7,131 453 of 7,359 | -6.1 points -6.7 to -5.6 | 14,490 | NCT05730387 Smart Discharges for Mom & Baby |
| Semaglutide vs DPP4 Inhibitors: deaths from any cause | 24 of 7,129 44 of 7,129 | -0.3 points -0.5 to -0.1 | 14,258 | NCT05768945 Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors |
| Rivaroxaban vs Warfarin: serious adverse events | 2,649 of 7,111 2,720 of 7,125 | -0.9 points -2.5 to 0.7 | 14,236 | NCT00403767 An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation |
| Baseline (Duke) vs Post Comfort Talk® Training: No-shows (Duke) | 395 of 4,446 779 of 9,658 | 0.8 points -0.2 to 1.8 | 14,104 | NCT02427737 Comfort Talk and Economic Outcomes in MRI |
| Phase I: Observational, Mother vs Phase I: Observational, Neonate: Post-natal Care Visits | 446 of 7,060 187 of 6,968 | 3.6 points 3.0 to 4.3 | 14,028 | NCT05730387 Smart Discharges for Mom & Baby |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=32
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT05643573-8b8fc6df",
"title": "Asundexian vs Apixaban: Number of Participants With Composite of Disabling Stroke (mRS ≥ 3), Critical Bleeding, or All-cause Mortality",
"summary": "51 of 7373 against 56 of 7364; risk difference -0.1 points, 95% interval -0.3 to 0.2; NCT05643573, A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke",
"record": "/library/comparisons/NCT05643573-8b8fc6df",
"nct_id": "NCT05643573",
"kind": "outcome",
"participants": 14737,
"risk_difference": {
"value": -0.0006874326684712852,
"lower": -0.003484280081333773,
"upper": 0.002092632516717355
},
"group_1": "51 of 7,373",
"group_2": "56 of 7,364",
"difference": "-0.1 points",
"interval": "-0.3 to 0.2",
"trial_title": "A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke"
},
{
"id": "NCT05643573-be4436d7",
"title": "Asundexian vs Apixaban: Number of Participants With Hemorrhagic Stroke",
"summary": "1 of 7373 against 6 of 7364; risk difference -0.1 points, 95% interval -0.2 to 0.0; NCT05643573, A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke",
"record": "/library/comparisons/NCT05643573-be4436d7",
"nct_id": "NCT05643573",
"kind": "outcome",
"participants": 14737,
"risk_difference": {
"value": -0.0006791445776768341,
"lower": -0.0016474438977877742,
"upper": 0.00009192138127663149
},
"group_1": "1 of 7,373",
"group_2": "6 of 7,364",
"difference": "-0.1 points",
"interval": "-0.2 to 0.0",
"trial_title": "A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=33",
"request_id": "dbnE-D3AWJn7NYP5"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant